![](https://ml.globenewswire.com/media/51670c91-d369-4a8c-8102-d393de9f6d19/small/download-jpg.jpg)
BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial – ...
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (NASDAQ: BIOA), a biopharmaceutical company focused on metabolic diseases, is facing a class-action lawsuit from shareholders who allege the company misled investors about the safety and …